Registration Timelines: 21 Days, 14 Days, 90 Days, One Year

1. Key takeaways

The four time limits in the Iraqi registration process correspond to four distinct matters: 21 days is the acceptance review period for pharmaceutical applications from submission; 14 days is the acceptance review period for company registration applications; 90 days is the ceiling for the review of a company registration from the date the file is complete; and one year is the ceiling for pharmaceuticals from the date the file is complete. Payment must be made within two weeks of the fee notice, and if the fee is not received within two months of the notice the application must be resubmitted. All of this appears in Section B of the Drug Registration Regulations published by the Registration Department of the Technical Affairs Directorate of the Iraqi Ministry of Health — a document with no number, no date and only secondary reproduction, graded secondary and not citable as a legal provision. GRZAN states clearly that the earlier website statements of a registration cycle of 8 to 24 months and official fees of IQD 500,000 to 15,000,000 were not found, as of October 29, 2026, in any legally reachable official channel; because the source sites were unreachable, no final assertion is made that no such official provisions exist. Both belong to the practical estimate and are not adopted here.

• 21 days: acceptance review of pharmaceutical applications, from the date of submission.
• 14 days: acceptance review of company registration applications, from the date of submission.
• 90 days: ceiling for the review of company registrations, from the date the file is complete.
• One year: ceiling for the review of pharmaceuticals, from the date the file is complete.
• Fees due within two weeks of the fee notice; if not received within two months, the application must be submitted anew.

2. Legal basis

The table below lists the sources cited in this article together with their document numbers, publication dates and the provisions relied upon.

Source grading: the Drug Registration Regulations is graded secondary and must not be cited as a legal provision (hosted at https://pharmexcil.com/uploadfile/ufiles/380351111_drug_regpdf.pdf; the official original was not obtained). The Country Profile 2020 is graded primary, indirectly verified (content obtained through indexed snippets).

Excerpts of the original provisions (Section B, English original):

• Item 2: the acceptance review must be completed within 21 days for pharmaceuticals and 14 days for companies, from the date of submission.
• Item 3: payment must be made within two weeks of the fee notice; where the fee is not received within two months, a new application must be filed.
• Item 4: the review period is not more than one year for pharmaceuticals and not more than 90 days for companies, from the date the file is complete.
• Country Profile 2020 Section 6.7: «there are no explicit and publicly available criteria for assessing applications … Thus, in-person follow-up is needed by a company representative».

3. Expert insights

Insight 1 | The four figures must be kept apart because they measure different clocks. The 21 days and the 14 days measure the acceptance review, whether the file is complete, starting from the date of submission; the 90 days and the one year measure the technical review, whether approval is granted, starting from the date the file is complete. The most common corporate error is to treat the 90 days as the period from contract signing to certificate and plan shipping backwards from it, finding that any supplementary filing resets the clock to zero.

Insight 2 | Cross-border comparison: enforceability of timelines correlates with institutional transparency. Annex VII of the EU MDR (EU) 2017/745 sets staged assessment timelines for notified bodies, and China’s registration measures fix statutory periods of 60 working days for technical review and 60 working days after supplementation. Iraq has the 90-day wording, yet the same government publication self-describes review criteria as non-public and follow-up as in-person — a deadline without remedy.

Insight 3 | Debunking: the registration cycle of 8 to 24 months was not found in any official source this round. The earlier website statements of 8 to 24 months and IQD 500,000 to 15,000,000 have no matching figures in the four time limits of Section B, the six items of Section D, the fee schedule of Section E or the general provisions of Section A, and none was retrieved from any legally reachable official channel. The likely origin is the compression of the per-product pharmaceutical review (ceiling one year) together with embassy legalization, supplementary filings and holiday shutdowns into a supposed statutory range. Because the source sites were unreachable, this article states only that nothing was retrieved; the figures are a practical estimate and are not adopted.

Insight 4 | Item 3 is the most easily overlooked and the most consequential clause of the section. Pay within two weeks; if the fee is not received within two months, apply anew — without the money, the entire completed acceptance review is void. This is not a grace period to be negotiated but a procedural lapse. GRZAN requires clients to chain the payment route, the receipt of funds and the counterparty’s confirmation at the time of submission, avoiding Friday and Iraqi public holiday bank closures.

Insight 5 | How should time limits from an undated document be used? Their value lies in revealing the procedural structure, acceptance then payment then review, and the proportionality: the company review of 90 days is far shorter than the pharmaceutical one year, corroborating that devices need no product registration. Their defect is that they cannot ground commitments or claims; use them as an internal scheduling reference, with each acceptance receipt as the real evidence.

4. Practical recommendations

• Write the schedule in four segments — acceptance review, file completion, payment window and technical review — annotating each with the clause relied on and a practical estimate note.
• From day 15 after submission, follow up the acceptance review in writing; if no reply comes, request written confirmation of whether the file has been deemed complete, the switch that starts the 90-day review.
• Start the payment process the day the fee notice arrives, ensure the funds arrive within two weeks, and retain the receipt until the registration is completed.
• Practical estimate: embassy legalization and document preparation usually consume most of the calendar time (commonly weeks to months, no official provision found); the contract should provide that legalization delays are not attributable to the service provider.
• Maintain an evidence timeline: archive the dates and reference numbers of submission receipts, payment vouchers and written follow-up records.

5. Verification checklist

• □ Read through Section B items 2, 3 and 4 and confirm the correspondence of the six figures: 21 days, 14 days, two weeks, two months, 90 days and one year.
• □ Check the wording of each starting point, from submission versus from complete file, and never mix them.
• □ Request the current process chart or forms from the Registration Department and confirm whether the time limits above still stand.
• □ Check whether Section 6.7 of the Country Profile 2020 is the latest version, as corroboration that the review criteria are not public.
• □ Delete or rewrite the statements of 8 to 24 months and IQD 500,000 to 15,000,000 in internal documents, replacing them with practical estimate.
• □ Check Iraqi public holidays and Friday closures and set the key payment dates accordingly.
• □ Re-verify whether the official documents cited in this article have been replaced by subsequent instructions or resolutions (verification baseline date of this article: October 29, 2026).

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iraqi market. Our team manages federal and Kurdistan registration applications, prepares reference-country dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com